BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 222 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,027,104 | -69.7% | 651,635 | -70.6% | 0.00% | -50.0% |
Q4 2023 | $13,277,506 | +122.8% | 2,216,612 | +161.8% | 0.00% | +100.0% |
Q2 2023 | $5,960,148 | -19.2% | 846,612 | -4.3% | 0.00% | -50.0% |
Q1 2023 | $7,379,757 | -44.2% | 884,863 | -23.2% | 0.00% | -33.3% |
Q4 2022 | $13,226,292 | -2.2% | 1,152,116 | +7.4% | 0.00% | -25.0% |
Q3 2022 | $13,521,262 | -35.6% | 1,073,116 | -45.9% | 0.00% | -20.0% |
Q2 2022 | $21,005,162 | +62.4% | 1,985,365 | +149.6% | 0.01% | +66.7% |
Q1 2022 | $12,935,285 | +30.1% | 795,528 | +10.8% | 0.00% | +50.0% |
Q4 2021 | $9,940,000 | -13.2% | 717,674 | -9.9% | 0.00% | -33.3% |
Q3 2021 | $11,448,000 | +322.6% | 796,674 | +364.9% | 0.00% | +200.0% |
Q2 2021 | $2,709,000 | +55.4% | 171,351 | 0.0% | 0.00% | – |
Q1 2021 | $1,743,000 | -33.3% | 171,351 | -51.1% | 0.00% | -100.0% |
Q4 2020 | $2,613,000 | -26.3% | 350,760 | -66.0% | 0.00% | 0.0% |
Q3 2020 | $3,545,000 | +36.9% | 1,032,093 | +89.9% | 0.00% | 0.0% |
Q2 2020 | $2,590,000 | – | 543,493 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |